ArticleJournal of autism and developmental disorders2025
Type 2 Diabetes-Related Avoidable Mortality Risk Among Individuals with Developmental Disabilities: A Comparison With Individuals With Other Disabilities and Those Without Disabilities : T2DM-Related Avoidable Mortality among Developmentally Disabled Individuals.
Article in Journal of autism and developmental disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to assess type 2 diabetes mellitus (T2DM)-related avoidable mortality in individuals with developmental disabilities using national claims data, comparing outcomes with those of other disabilities and non-disabled controls.
methodsWe used de-identified national claims data from the National Health Insurance Service merged with Causes of Death Statistics. The cohort included individuals over 30 years old with developmental disabilities who were newly diagnosed with T2DM between 2012 and 2016. Matched controls (non-disabled, mild, and severe disabilities) were selected based on sex, age, income proxy, and region. T2DM-related avoidable mortality (ICD-10 code "E11") within 1, 3, and 5 years was assessed using multiple logistic regression, adjusted for sociodemographic factors and comorbidities.
resultsT2DM-related avoidable mortality rates in the developmental disability group were 0.05%, 0.23%, and 0.55% at 1, 3, and 5 years post-diagnosis, respectively-lower than those in individuals with severe disabilities but higher than those of individuals without disabilities. Multiple logistic regression revealed no significant difference in 1-year mortality between individuals with developmental disabilities and those without disabilities; however, the risk was significantly higher at 3 years (OR = 4.84; 95% CI: 1.80-13.00) and 5 years (OR = 3.82; 95% CI: 2.14-6.81). Compared with individuals with mild disabilities, the 5-year mortality risk was also higher (OR = 2.41; 95% CI: 1.38-4.21).
conclusionIndividuals with developmental disabilities exhibit significantly higher T2DM-related avoidable mortality than non-disabled and mild disability groups, highlighting critical gaps in healthcare accessibility. Strengthening targeted interventions and support services is essential to reducing avoidable deaths and improving health outcomes in this population.
Indexed as
Identifiers
41351782What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.